MedTrace Logo

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

NCT07132749 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-01-08

No results posted yet for this study

Summary

This clinical trial is a prospective, observational, multicenter cohort study evaluating the efficacy and safety of NEPA (netupitant/palonosetron) in patients with HER2-positive or HER2-low advanced breast cancer treated with T-DXd

Conditions

  • Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd
  • Patients With HER2-low Advanced Breast Cancer Treated With T-DXd

Sponsors & Collaborators

  • Helsinn Healthcare SA

    collaborator INDUSTRY

  • Yeon Hee Park

    lead OTHER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07132749 on ClinicalTrials.gov